Interestingly, neither LNCaP nor 22Rv1 prostate cancer cells showed substantially increased levels of endogenous GATA2 protein after treatment with the proteasome inhibitor MG132 (Figure 1E,F). This evidence concerns the gene GATA2 and prostate cancer.